SHARE NOW
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
The clinical-stage biotech company, Eureka Therapeutics, Inc., is focused on developing novel T-cell therapies to treat cancers. Its technology is centered around its proprietary ARTEMIS® Cell Receptor Platform and E-ALPHA® Phage Display platform.
“We are delighted to partner with CIRM and are honored by their recognition of the potential of our ET140203 ARTEMIS T-cell therapy program,” commented Dr. Cheng Liu, President and CEO of Eureka Therapeutics.
The grant will support Eureka’s ongoing clinical trial of ARTEMIS® T-Cell Therapy, ARYA-2 Phase I study of ET140203, for the treatment of pediatric patients with refractor/relapsed liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).
“We are deeply appreciative of the CIRM Application Review Subcommittee members’ unanimous vote to support our effort to make novel cellular therapies available to the medically underserved pediatric liver cancer population,” expressed Dr. Pei Wang, VP of Clinical Development and Principal Investigator under the CIRM grant.
How are you enjoying this news article? Let us know your thoughts, here >>
“Pediatric liver malignancies are rare, have no FDA-approved treatment options, and remain difficult to treat,” added Liu.
The ARYA-2 study of ET140203 is part of Eureka’s liver cancer portfolio which includes the ongoing ARYA-1 and ARYA-3 studies of adult patients with HCC. The ARYA-3 study uses ECT204 ARTEMIS T cells to target the Glypican 3 (GPC3) protein expressed on the surface of liver cancer cells.
The modified T cells extracted from a patient’s blood once expanded in the laboratory and reinfused into the patient, will specifically target the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells and destroy the AFP-expressing liver cancer cells.
“We look forward to collaborating with our clinical partners and the CIRM team to bring ET140203 to patients,” said Wang.
CIRM is one of the world’s largest institutions dedicated to ‘accelerating world-class science to deliver transformative regenerative medicine treatments’ to those with incurable diseases or disorders to help with unmet medical needs.
Source: Eureka Therapeutics, Inc.
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
